Spring Bank Pharma human trials on track
Courtesy
Hopkinton's Spring Bank Pharmaceuticals has announced that the second phase of human trials for its hepatitis medicine are on track as the company reported $4.1 million in losses in the third quarter.
According to a release from Spring Bank sent out last week, the company is on track to report preliminary results from the study in the first half of 2017 with top line results for all patients anticipated by year-end 2017.
Losses continue as the company pushes SB 9200 through phase 2a clinical trials. Spring Bank reported a rise in net losses in the third quarter to $4.1 million from $3.4 million in the same quarter of 2015. Research and development expenses for the quarter ended September 30, 2016 were $2.7 million as compared to $2.1 million for the same period in 2015, with the rise being attributed to activities related to the clinical trial, according to the company.
At the end of the quarter, Spring Bank had $15.6 million in cash, cash equivalents and marketable securities.
WBJ Web Partners
Most Recent
Most Recent
0 Comments